Lymphedema Tailwinds And AI Workflow Efficiencies Will Drive Significant Long Term Upside

Catalysts

About Tactile Systems Technology

Tactile Systems Technology develops and commercializes medical devices that treat chronic lymphedema and airway clearance conditions, focusing on home-based, clinically validated therapies.

What are the underlying business or industry changes driving this perspective?

• Accelerating penetration of a large, historically underdiagnosed lymphedema patient population supported by favorable Medicare policy shifts, including the NCD that streamlines access to advanced pumps such as Flexitouch, is cited as a driver of higher unit volumes and revenue growth.
• Rapid AffloVest adoption through preferred positioning with the top 10 respiratory DMEs and rising bronchiectasis awareness, including from new drug launches that expand disease recognition, is reported to be driving share gains and a mix shift toward the faster growing airway clearance line, which in turn supports overall revenue growth and operating leverage.
• Evidence backed differentiation, highlighted by positive randomized data in head and neck lymphedema and a strong clinical publication pipeline, is cited as a factor that could help unlock new coverage policies and indications and support pricing power and net margins over time.
• Digital and AI driven workflow enhancements in order intake, documentation review and patient engagement, combined with a scaled Salesforce CRM enabled field force, are intended to structurally lower per order servicing costs and increase conversion yield, which would be supportive of EBITDA margin expansion as revenue grows.
• Next generation product innovation, including a lighter, connected AffloVest and ongoing upgrades to advanced compression systems, is intended to strengthen the company’s position in home based chronic care and support recurring device replacement and accessory revenue, higher lifetime patient value and earnings growth.

Assumptions

This narrative explores a more optimistic perspective on Tactile Systems Technology compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Tactile Systems Technology's revenue will grow by 10.0% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 5.8% today to 9.4% in 3 years time.
• The bullish analysts expect earnings to reach $38.8 million (and earnings per share of $1.73) by about December 2028, up from $18.2 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $29.7 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 19.5x on those 2028 earnings, down from 34.7x today. This future PE is lower than the current PE for the US Medical Equipment industry at 30.1x.
• The bullish analysts expect the number of shares outstanding to decline by 5.3% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.73%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• A meaningful portion of current growth depends on favorable Medicare policy such as the new NCD and on commercial payers eventually revising experimental and investigational language for head and neck lymphedema. If policy interpretation tightens again or payers are slow to update coverage, patient access could stall and weigh on lymphedema revenue and overall earnings growth over the long term.
• The company is making substantial, ongoing investments in sales head count, CRM systems, AI enabled order operations and omnichannel patient engagement that are expected to drive scalability. If these transformation programs prove more costly, slower to ramp or less effective than planned, operating expenses could structurally outpace productivity gains and compress net margins and EBITDA over time.
• AffloVest is currently growing at very high rates and increasingly contributes to the mix. Management already cautions that this growth is unlikely to be sustained at current levels, and if broader bronchiectasis market awareness or DME partner demand normalizes, the airway clearance segment could decelerate sharply and reduce future total revenue growth and profit expansion.
• Management is leaning into share repurchases and highlighting free cash flow strength. As the company also retires debt and funds product innovation and clinical evidence generation, any downturn in cash generation from slower sales, reimbursement friction or higher tariffs could constrain strategic flexibility and ultimately pressure earnings and valuation multiples.
• The bullish view assumes Tactile will at least grow in line with its estimated 10 percent lymphedema market. Persistent diagnosis gaps, rising competition from entrenched players in compression and airway clearance, or slower than expected adoption of newer offerings like Nimbl and the next generation AffloVest could limit share gains and result in structurally lower revenue growth and profitability than implied in the optimistic scenario.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Tactile Systems Technology is $32.0, which represents up to two standard deviations above the consensus price target of $24.0. This valuation is based on what can be assumed as the expectations of Tactile Systems Technology's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $32.0, and the most bearish reporting a price target of just $16.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2028, revenues will be $415.0 million, earnings will come to $38.8 million, and it would be trading on a PE ratio of 19.5x, assuming you use a discount rate of 7.7%.
  
• Given the current share price of $28.23, the analyst price target of $32.0 is 11.8% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.